Authors: Steve Miller Shalini Sharda James Rodrigue Paulette Mehtaa
Publish Date: 2002/11/01
Volume: 76, Issue: 4, Pages: 365-369
Abstract
Thalidomide is being increasingly used after stem cell transplantation as immunosuppression for patients with chronic graftversushost disease as well as for antiangiogenesis effects in patients with multiple myeloma brain tumors leukemia or other malignancies The goal of this study was to determine if thalidomide improved the quality of life by virtue of its associated sleeppromoting anxietyreducing antiwasting and antidiarrheal effects We therefore studied 28 patients with resistant chronic graftversushost disease who were treated with thalidomide 13 patients or other immunosuppressive drugs 15 and compared them with healthy control subjects 16 All patients completed qualityoflife questionnaires prospectively before beginning regimens of thalidomide or other immunosuppressive drugs and completed similar questionnaires at 3 and 6month intervals thereafter The Transplant Symptom Frequency score was similar for healthy control subjects and both groups of patients with chronic graftversushost disease regardless of whether they had received thalidomide or not Quality of sleep was equally poor in patients who received or did not receive thalidomideThe most common complaint of patients with chronic graftversushost disease was fatigue followed in frequency by overeating The control group had similar concerns This pilot study suggests that patients with chronic graftversushost disease have a quality of life similar to that of their health care workers regardless of whether they are treated with thalidomide or other immunosuppressive drug and that fatigue and overeating are the most common complaints Int J Hematol 200276365369
Keywords: